key: cord-0851686-89a5wpvz
authors: Robbins, Melody J; Floroff, Catherine; Ingemi, Amanda; Kaplan, Marcus C
title: Evaluation of discharge prescribing after rescheduling of gabapentin as a controlled substance
date: 2021-07-14
journal: Am J Health Syst Pharm
DOI: 10.1093/ajhp/zxab288
sha: d91d588bc7f3b7987ea841cff86ac05d5378a6c3
doc_id: 851686
cord_uid: 89a5wpvz

DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: Gabapentin has increasingly been identified as a drug of abuse, especially when used concurrently with opioids. Rescheduling gabapentin as a schedule V controlled substance may strengthen monitoring and prescribing restrictions. The purpose of this study was to characterize the impact of rescheduling gabapentin from a nonscheduled to a schedule V substance in Virginia on discharge prescribing patterns in a health system. METHODS: This was a retrospective, pre-post, multicenter chart review conducted at 4 sites. Data from 3 months before gabapentin rescheduling (prerescheduling group) and 3 months after gabapentin rescheduling (postrescheduling group) were evaluated. The primary outcome was the percentage of newly prescribed gabapentin prescriptions upon discharge, which was compared between the pre- and postrescheduling groups. RESULTS: A similar percentage of gabapentin prescriptions were newly prescribed in the prerescheduling group as compared to the postrescheduling group (55.0% vs 50.0%, P = 0.479). Gabapentin prescribing characteristics did not differ between the groups for new gabapentin prescriptions (n = 55 in the prerescheduling group, n = 50 in the postrescheduling group). Concomitant discharge prescribing of benzodiazepines (5.5% vs 2.0%, P = 0.619) and opioids (45.5% vs 60.0%, P = 0.136) did not differ significantly between the postrescheduling group and prerescheduling group for new gabapentin prescriptions. However, fewer opioid prescriptions exceeded 90 daily morphine milligram equivalents (MME) in the postrescheduling group as compared to the prerescheduling group for new gabapentin prescriptions (36.0% vs 20.0%, P = 0.020). CONCLUSION: Gabapentin prescribing practices did not differ before and after rescheduling of gabapentin as a controlled substance. There was a trend toward dosages with reduced daily MME for concomitant opioid prescriptions after rescheduling. However, additional investigation with larger studies over longer periods of time is needed to discover whether gabapentin rescheduling significantly changes prescribing practices.

M a n u s c r i p t investigation with larger studies over longer periods of time is needed to discover whether gabapentin rescheduling significantly changes prescribing practices.

Keywords: controlled substances, gabapentin, opioid, substance-related disorders Overuse of gabapentin and evidence suggesting that gabapentin possesses abuse potential have both recently been reported. 1,2 Opioid prescribing rates have been shown to be significantly higher among patients who are prescribed gabapentin. 3 Fatalities are not common when gabapentin is used alone, but gabapentin abuse has been shown to result in increased mortality with concomitant opioid use. 2, 4, 5 Gabapentin used with opioids, at single doses of greater than 900 mg, increased the odds of opioid-related death by 60% in comparison to use of opioids alone. 4 Strategies to prevent misuse and abuse of gabapentin are warranted to prevent morbidity and mortality from overdose.

Gabapentin was the tenth most commonly prescribed medication in the United States in 2016 and has been increasingly prescribed in recent years for off-label indications such as neuropathic pain, postoperative pain, and alcohol dependence and withdrawal. 3, 6, 7 The exact mechanism of this -aminobutyric acid (GABA)-mimetic agent has not been fully elucidated, but gabapentin is known to bind to the  2  subunit of voltage-gated calcium channels and exhibit antinociceptive, anticonvulsant, and anxiolytic properties. 7 Supratherapeutic doses of gabapentin may lead to sedation, dissociation, relaxation, improved sociability, empathy, and a "high," especially when gabapentin is used with other psychoactive substances such as opioids, cannabis, and/or benzodiazepines. 2, 8 Reasons for abuse are hypothesized to include the availability of and access to gabapentin in the setting of increasing control of opioid and benzodiazepine prescribing, potentiation of opioid A c c e p t e d M a n u s c r i p t effects, increasing off-label use, and/or the inability of drug urine screens to detect gabapentin. 1, 2, [9] [10] [11] Risk factors for gabapentin abuse include a history of opioid abuse, cocaine use, cannabis use, or benzodiazepine use, as well as psychiatric diagnoses and young age. 2, 12 Evidence of gabapentin's abuse potential recently prompted Virginia to reschedule gabapentin to schedule V, which took effect on July 1, 2019. 13 This rescheduling of gabapentin requires monitoring through the Virginia Prescription Monitoring Program.

Gabapentin prescriptions cannot be dispensed or refilled more than 6 months after they are first issued, and prescriptions cannot exceed 5 refills. 13 Other states that have rescheduled gabapentin to schedule V include Kentucky, Ohio, Tennessee, and West Virginia. The Drug Enforcement Administration has not yet nationally scheduled gabapentin. 3, 14 To our knowledge, there is no existing literature characterizing the impact of state gabapentin rescheduling on gabapentin prescribing activity. This study aimed to characterize the impact of rescheduling gabapentin from a noncontrolled medication to a schedule V controlled substance in Virginia on discharge prescribing patterns of gabapentin in a health system.

This study was a retrospective electronic medical record evaluation conducted at 4 sites evaluating data from 3 months before and 3 months after gabapentin rescheduling from a nonscheduled to a schedule V substance. The 4 sites in the study included a large academic medical center and 3 community hospitals within a single healthcare system. The study was reviewed by the participating healthcare system's institutional review board and found to be exempt.

A c c e p t e d M a n u s c r i p t Adults aged 18 to 89 years who were discharged with a prescription for gabapentin after emergency department (ED), observation, or inpatient admission were included in this study. Eligible patients were identified from the electronic health record (EHR), and those with incomplete records in which data collection could not be performed were excluded from the analyses. Patients whose gabapentin prescription was discontinued within 24 hours of ordering were also excluded. The patients included were stratified to either a prerescheduling group or a postrescheduling group, corresponding to before and after the Study population characteristics, encompassing demographics and clinical factors, were extracted from the EHR. Daily doses for home opioid medications were converted to daily morphine milligram equivalents (MME), stratifying doses in groups with 50 MME or lower, 51 to 89 MME, and 90 MME or higher, which correspond to low, medium, and high MME as defined by the Centers for Disease Control and Prevention. 15 To evaluate prescribing habits, the primary outcome was the difference in the percentage of newly prescribed (NP) gabapentin prescriptions among all gabapentin prescriptions between the pre-and postrescheduling groups. NP gabapentin prescriptions were defined as gabapentin prescriptions for patients without gabapentin on their A c c e p t e d M a n u s c r i p t preadmission list of medications. Other gabapentin prescriptions were considered to be continued-from-home gabapentin prescriptions, as gabapentin was on the preadmission medication list for the patient.

All secondary outcomes were examined by comparing the pre-and postrescheduling groups for only NP gabapentin discharge prescriptions to more accurately reflect the prescribing activity of the physicians from our healthcare system. Secondary outcomes investigated across the NP pre-and postrescheduling groups included characteristics of NP gabapentin prescriptions, such as total daily dose, frequency, number of refills given, and indications for use. Additional secondary outcomes included the number of concomitant benzodiazepine and opioid discharge prescriptions written. Opioid prescriptions were further stratified into those with low, medium, and high MME as defined above. 15 Statistical analysis. Data are presented as mean (SD), median (interquartile range), or count (%) as appropriate. All statistical analyses were performed using IBM SPSS Statistics Software version 24.0 (IBM Corporation, Armonk, NY). A P value below 0.05 was considered to be statistically significant.

Characteristics for the representative sample were compared between the pre-and postrescheduling groups using a Student's t test for continuous data and a  2 or Fisher's exact test for categorical data as appropriate.

The percentage of NP gabapentin prescriptions was compared between the pre-and postrescheduling groups using a  2 test. NP groups were defined from this analysis as an NP prerescheduling group (n = 55 patients) and an NP postrescheduling group (n = 50 patients).

All further secondary analyses were performed in this population using a  2 or Fisher's exact test as appropriate. Table 2 . Home use of benzodiazepine, opioid, and other analgesic medications did not differ between the 2 groups. A higher proportion of patients in the NP postrescheduling group had a substance abuse disorder (P = 0.002) or other psychiatric history (P = 0.045). The total daily dose for NP gabapentin discharge prescriptions was similar in the pre-and postrescheduling groups, as shown in Table 3 . A M a n u s c r i p t higher percentage of patients in the NP prerescheduling group had gabapentin prescriptions indicated for acute pain (P = 0.080).

The number of concomitant opioid and benzodiazepine discharge prescriptions was compared in the NP prerescheduling group and the NP postrescheduling group (Table 3) .

Prescriptions for those discharged on concomitant opioid prescriptions were stratified on the basis of total daily MME into groups with low, medium, and high MME, as shown in Figure 3 . While the number of opioid prescriptions classified as having low and medium total daily MME did not differ between the 2 groups, the number of opioid prescriptions that were classified as having high total daily MME (≥90 MME) was significantly different (P = 0.020), with the NP prerescheduling group having more as compared to the NP postrescheduling group.

Our analysis did not demonstrate any statistically significant changes in gabapentin prescribing within our health system after gabapentin rescheduling from a noncontrolled to a schedule V substance in Virginia. To our knowledge, this is the first study to examine gabapentin prescribing after state rescheduling. Although gabapentin prescribing did not differ significantly after rescheduling, concomitant opioid prescriptions trended toward dosages with lower daily MME. This suggests that physicians may have been more mindful of the risks of high opioid doses in combination with gabapentin after rescheduling and modified their prescribing practices as a result.

After an acute overdose with gabapentin alone, adverse events are reported to be relatively mild. 2 However, when gabapentin is used concurrently with other respiratory depressants such as benzodiazepines and opioids, fatalities are common, with a reported A c c e p t e d M a n u s c r i p t 90% of gabapentin-related deaths involving opioids. 2 In US toxicological data in those with impaired driving, among people with gabapentin-positive blood samples, 44% had used benzodiazepines and 44% had used opioids, while some had used other central nervous system (CNS) depressants such as antidepressants and alcohol. 1 In our study, relatively few benzodiazepine prescriptions as compared to opioid prescriptions were written on discharge concomitantly with a gabapentin prescription. Gabapentin is easily accessed and most often obtained by legitimate medical prescription from healthcare providers, 2 rather than by illegal acquisition. Because of this ease of access to gabapentin, it is crucial that providers take caution in prescribing it and consider the concomitant use of other CNS depressants as a potential risk factor for misuse or negative outcomes.

Gabapentin is utilized off-label for many psychiatric-related conditions such as alcohol use disorder and anxiety, although evidence does not support its use for treatment of opioid use disorders. 16 However, these psychiatric-related conditions are known risk factors for gabapentin misuse and abuse. Many patients in our study had these psychiatric comorbidities of concern. Thus, more caution may be needed in prescribing gabapentin to patients with these comorbidities, and future studies could consider the incidence of gabapentin abuse specifically in populations with known psychiatric conditions for which gabapentin is commonly prescribed.

Limitations of this study included its retrospective nature, relatively small sample size, and short data collection time periods. Another notable source of bias might be the collection of data for the 3 months directly preceding and the 3 months directly following gabapentin rescheduling. It is unknown whether any provided education or lack thereof in these time periods may have played a role in the prescribing patterns of providers. While effects from physician staffing changes between the 2018 prerescheduling period and the A c c e p t e d M a n u s c r i p t 2019 postrescheduling period could not be ruled out, any effects were minimized by ensuring that the study took place only at hospitals with the same shared practice group of rotating physicians. Lastly, the findings of this study only reflect hospital prescribing, which may be less impacted by medication scheduling restrictions than prescription refills, which are often limited in this setting. Future studies should be conducted to validate the findings of this work.

Gabapentin rescheduling to a controlled substance in Virginia was not shown to affect its prescribing on discharge in our health system. However, the observed decrease in dosages for concurrently prescribed opioids may prompt other states to consider the possible positive effects of scheduling gabapentin. The impact of rescheduling gabapentin as a controlled substance at a state level is not widely known overall. Ultimately, future investigations like this one with larger sample sizes and longer durations may pave the way to uncovering further strategies for prevention of gabapentin misuse and abuse at a state and national level. M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

Gabapentin misuse, abuse, and diversion: a systematic review

Abuse and misuse of pregabalin and gabapentin

Trends in gabapentin prescribing in a commercially insured U.S. adult population

Gabapentin, opioids, and the risk of opioidrelated death: a population-based nested case-control study

A decade of gabapentinoid misuse: an analysis of the European Medicine Agency's 'suspected adverse drug reactions

Gabapentin and pregabalin for pain-is increased prescribing a cause for concern?

Gabapentin: pharmacology and its use in pain management

Prescribing gabapentin off label: perspectives from psychiatry, pain and neurology specialists

Gabapentin for off-label use: evidencebased or cause for concern?

Gabapentin use in a managed Medicaid population

Off-label prescribing among office-based physicians

Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured

Board of Pharmacy, Virginia Department of Health Professions. Scheduling of gabapentin

Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance

About CDC's opioid prescribing guideline

Gabapentin therapy in psychiatric disorders: a systematic review

The authors would like to acknowledge the contributions of those who participated in various stages of this research: Megan D. Hoesly, PharmD, and Terrell Brown.

The authors have declared no potential conflicts of interest.

A c c e p t e d M a n u s c r i p t